Communiqués Innovent Biologics, Inc.

Actions

1801

KYG4818G1010

Temps Différé Hong Kong S.E. Autres places de cotation 09:33:05 27/06/2024			Varia. 5j.	Varia. 1 janv.
39,15 ^HKD	-0,89 %		+5,38 %	-8,42 %

25/06	Innovent Biologics, Inc. présente les résultats de la première étude de phase 3 sur le mazdutide pour la gestion du poids lors de la 84e session scientifique de l'ADA	CI
13/06	Innovent Biologics, Inc. reçoit la désignation Fast Track de la FDA des États-Unis pour IBI343 (TOPO1i anti-CLDN18.2 ADC) en tant que monothérapie pour le traitement du cancer du pancréas avancé	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Innovent Reports Oncology Pipeline Updates at Investor Meeting	20/06	AQ
Innovent Announces Picankibart Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA	29/05	AQ
Innovent Announces the New Drug Application of IBI311 has been accepted by the NMPA of China for Thyroid Eye Disease	22/05	AQ
Innovent Biologics Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 and IBI343	20/05	AQ
Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints	10/05	AQ
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer	01/05	AQ
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04	AQ
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04	AQ
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer	06/03	AQ
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China	29/12	AQ
Innovent Releases Final Analysis Results of ORIENT-15, the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023	17/04/23	AQ
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT in Two New Indications Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications	19/01/23	AQ
Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China	10/08/22	AQ
China NMPA Approves TYVYT (sintilimab) In Combination With Chemotherapy For Gastric Cancer	30/06/22	AQ
OPKO Health : to Develop and Commercialize RAYALDEE in Greater China with Nicoya Therapeutics	22/06/21	AQ
Innovent Biologics : Form of Proxy for use at the Annual General Meeting to be held on Thursday, June 24, 2021	30/04/21	PU
Innovent Biologics : PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	30/04/21	PU
Innovent Biologics : INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON SALES OF TYVYT (SINTILIMAB INJECTION) IN THE FIRST QUARTER OF 2021	27/04/21	PU
Innovent Biologics : GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES	31/03/21	PU
Innovent Biologics : Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress	30/03/21	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Innovent Biologics, Inc.

Actions

1801

KYG4818G1010

Communiqués

Filtres